Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.61 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1185872 | 0.83 | GSR (0.61) | GSRMMP2MMP9MMP8ENPP2 | |
| SCHEMBL10831304 | 0.82 | GSR (0.59) | GSRMMP2MMP9MMP8ENPP2 | |
| SCHEMBL8233398 | 0.82 | GSR (0.59) | GSRMMP2MMP9MMP8ENPP2 | |
| SCHEMBL22584909 | 0.82 | GSR (0.59) | GSRMMP2MMP9MMP8ENPP2 | |
| SCHEMBL16923800 | 0.82 | GSR (0.59) | GSRMMP2MMP9MMP8ENPP2 | |
| SCHEMBL125350 | 0.82 | GSR (0.59) | GSRMMP2MMP9MMP8ENPP2 | |
| SCHEMBL15556865 | 0.82 | GSR (0.59) | GSRMMP2MMP9MMP8ENPP2 | |
| SCHEMBL28990483 | 0.82 | GSR (0.59) | GSRMMP2MMP9MMP8ENPP2 | |
| Hydrochloric Acid SCHEMBL15465891 | 0.80 | GSR (0.60) | GSRMMP2MMP9MMP8ENPP2 | |
| SCHEMBL25876517 | 0.80 | GSR (0.57) | GSRMMP2MMP9MMP8ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4387617-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | The Regents of the University of California (US) | 2024-06-26 | — | — | EP | disclosed |
| WO-2023023156-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023023156-A1 | ACID CERAMIDASE INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-02-23 | — | — | WO | disclosed |
| CN-110015983-A | 1,2- dicarbapentaborane class compound and its synthetic method | 华东师范大学 | 2019-07-16 | — | — | CN | disclosed |
| US-20080044350-A1 | Optical Imaging Contrast Agents for Imaging Lung Cancer | GE HEALTHCARE AS (NO) | 2008-02-21 | — | — | US | disclosed |
| US-20080044350-A1 | Optical Imaging Contrast Agents for Imaging Lung Cancer | GE HEALTHCARE AS (NO) | 2008-02-21 | — | — | US | disclosed |
| US-20080044350-A1 | Optical Imaging Contrast Agents for Imaging Lung Cancer | GE HEALTHCARE AS (NO) | 2008-02-21 | — | — | US | disclosed |
| US-20070212305-A1 | Optical Imaging Contrast Agents For Imaging Lung Cancer | AMERSHAM HEALTH AS (NO) | 2007-09-13 | — | — | US | disclosed |
| US-20070212305-A1 | Optical Imaging Contrast Agents For Imaging Lung Cancer | AMERSHAM HEALTH AS (NO) | 2007-09-13 | — | — | US | disclosed |
| US-20070212305-A1 | Optical Imaging Contrast Agents For Imaging Lung Cancer | AMERSHAM HEALTH AS (NO) | 2007-09-13 | — | — | US | disclosed |
| EP-1667734-A2 | OPTICAL IMAGING OF COLORECTAL CANCER | GE Healthcare AS (NO) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005058370-A1 | OPTICAL IMAGING CONTRAST AGENTS FOR IMAGING LUNG CANCER | AMERSHAM HEALTH AS (NO) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058372-A1 | OPTICAL IMAGING CONTRAST AGENTS FOR IMAGING LUNG CANCER | AMERSHAM HEALTH AS (NO) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005030266-A2 | OPTICAL IMAGING OF COLORECTAL CANCER | AMERSHAM HEALTH AS (NO) | 2005-04-07 | — | — | WO | disclosed |
| US-6869968-B1 | Such as 3-(4-fluorophenyl)-4-(4-methysulphonylphenyl)-2-(3H)-oxazolone; for treating colorectal cancer, fevers, and inflammation | ALLMIRALL PRODESFARMA S.A. (ES) | 2005-03-22 | — | — | US | disclosed |
| EP-0888316-B1 | 2-(3H)-OXAZOLONE DERIVATIVES AND THEIR USE AS COX-2 INHIBITORS | ALMIRALL PRODESFARMA SA (ES) | 2000-11-02 | — | — | EP | disclosed |
| EP-1017685-A1 | NEW 2-(3H)-OXAZOLONE DERIVATIVES | ALMIRALL-PRODESFARMA, S.A. (ES) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999014205-A1 | NEW 2-(3H)-OXAZOLONE DERIVATIVES | ALMIRALL PRODESFARMA S.A. (ES) | 1999-03-25 | — | — | WO | disclosed |
| EP-0888316-A1 | 2-(3H)-OXAZOLONE DERIVATIVES AND THEIR USE AS COX-2 INHIBITORS | ALMIRALL-PRODESFARMA, S.A. (ES) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034882-A1 | 2-(3H)-OXAZOLONE DERIVATIVES AND THEIR USE AS COX-2 INHIBITORS | ALMIRALL PRODESFARMA, S.A. (ES) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044350-A1 | Optical Imaging Contrast Agents for Imaging Lung Cancer | KLK3, ROCK1, SMO | GSR 1819/4885MMP2 2528/4885MMP9 709/4885 |
| US-20070212305-A1 | Optical Imaging Contrast Agents For Imaging Lung Cancer | IQGAP1, AQP3, ROCK1 | GSR 2863/4885MMP2 2845/4885MMP9 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.